EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudie

Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial

Subrata Pahari iD, Sandipan Hazra iD, Partha Pratim Das iD

Pain Medicine · 01.11.2026 · 27 (11) · 1200-1209

DOI: 10.1093/pm/pnag093 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 03.08.2026. Verfasst von Subrata Pahari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Medicine and Rehabilitation, Nil Ratan Sircar Medical College & Hospital, Kolkata, India. Hauptthemen laut MEDLINE: Lidocaine, Low Back Pain, Anesthetics, Local, Chronic Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Evidence supporting repeated intravenous lidocaine infusions for probable nociplastic chronic non-specific low back pain remains limited despite its use as a centrally acting analgesic in several chronic pain conditions.

Objective

To evaluate whether repeated intravenous lidocaine infusions provide clinically meaningful benefit beyond placebo for pain reduction in probable nociplastic chronic non-specific low back pain.

Setting

Department of Physical Medicine and Rehabilitation, NRS Medical College and Hospital.

Participants

Eighty-four adults with chronic non-specific low back pain and probable nociplastic pain features.

Interventions

Participants were randomized equally to receive either intravenous lidocaine (1 mg/kg bolus followed by 4 mg/kg infusion weekly for 4 weeks) or placebo saline infusion. All participants received background multimodal pain management consisting of amitriptyline and aerobic exercise. Main Outcomes The primary endpoint was the between-group difference in Visual Analogue Scale (VAS) pain intensity at 3 months. Therapeutic equivalence was assessed using a prespecified equivalence margin of ±1.5 VAS units and the two one-sided tests (TOST) framework. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index [PSQI]) and functional disability (Quebec Back Pain Disability Scale [QBPDS]).

Results

At 3 months, the between-group difference in VAS was 0.24 (90% CI, −0.33 to 0.81), entirely within the predefined equivalence bounds, confirming therapeutic equivalence (TOST P < .001). Both groups improved significantly over time without a significant group × time interaction. Improvement in sleep quality was greater in the lidocaine group (mean difference in change score, 1.81; 95% CI, 0.49-3.14; P = .027). Functional improvement numerically favored lidocaine, although continuous disability outcomes were not significantly different. Adverse events were more common in the lidocaine group but were mild, transient, and self-limiting.

Conclusion

Repeated intravenous lidocaine infusions did not provide additional analgesic benefit over saline infusions administered alongside multimodal pain management in patients with probable nociplastic chronic non-specific low back pain. Relevance These findings support prioritizing evidence-based multimodal pain management, including exercise and centrally acting pharmacological therapy, over routine adjunctive intravenous lidocaine for probable nociplastic chronic non-specific low back pain. Clinical trial registration number CTRI/2024/07/070888. Clinical trials Registry-India (CTRI) https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTA4ODk1&Enc=&userName=.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LidocaineLow Back PainAnesthetics, LocalChronic PainHumansNociplastic PainFemaleMaleAdultPain MeasurementMiddle AgedInfusions, IntravenousPain ManagementDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

chronic non-specific low back painequivalence trialintravenous lidocainemultimodal pain managementnociplastic pain

Substanzen

LidocaineAnesthetics, Local

Autor:innen und Institutionen

  • Department of Physical Medicine and Rehabilitation, Nil Ratan Sircar Medical College & Hospital, Kolkata, India.

ORCID-Profile: Subrata Pahari, Sandipan Hazra, Partha Pratim Das

Zitieren

APA

Pahari, S., Hazra, S., & Das, P. P. (2026). Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial. Pain Medicine, 27(11), 1200-1209. https://doi.org/10.1093/pm/pnag093

Vancouver

Pahari S, Hazra S, Das PP. Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial. Pain Medicine. 2026;27(11):1200-1209. doi:10.1093/pm/pnag093

BibTeX
@article{Pahari2026,
  author = {Pahari, Subrata and Hazra, Sandipan and Das, Partha Pratim},
  title = {Intravenous lidocaine does not provide additional pain reduction beyond placebo in probable nociplastic chronic low back pain: a randomized controlled equivalence trial},
  journal = {Pain Medicine},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {1200--1209},
  doi = {10.1093/pm/pnag093}
}
Kostenlos starten →